前列腺特异性抗原登记错误对临床研究的影响:退伍军人健康管理局数据
本研究比较了基于癌症登记PSA值与基于电子健康记录实验室PSA值定义的前列腺癌队列。结果显示两组队列一致性有限,最低58%(PSA<4.0 ng/ml),最高89%(PSA 4.0-10.0 ng/ml),且仅基于登记PSA值分组的患者总生存期存在显著差异。仅依赖癌症登记PSA值可能引入错分和结局差异。
要点
- 仅用癌症登记PSA值定义队列与电子健康记录实验室值一致性有限。
- PSA<4.0 ng/ml组一致性最低(58%),4.0-10.0 ng/ml组最高(89%)。
- 仅基于登记PSA值分组与基于登记加实验室值分组的总生存期显著不同。
核心结论
- 仅基于癌症登记PSA值定义的队列可能存在高错分率,可引入关键特征差异并导致临床结局的显著不同。
研究设计与样本
- 利用退伍军人健康管理局数据定义前列腺癌男性样本队列,分别按PSA<4.0、4.0-10.0、10.0-20.0和20.0-98.0 ng/ml分组。
- 比较使用退伍军人事务中央癌症登记PSA值与金标准电子健康记录实验室文件结果时各队列的构成和患者总生存期。
主要发现
- 基于癌症登记PSA值与基于电子健康记录实验室文件定义的队列之间一致性有限。
- PSA<4.0 ng/ml患者一致性最低为58%,PSA 4.0-10.0 ng/ml患者一致性最高为89%。
- 每个队列中,仅基于癌症登记PSA值分组与基于登记和实验室文件PSA值分组的患者总生存期存在显著差异。
临床怎么用
- 临床研究中定义PSA队列时应优先使用电子健康记录实验室值作为金标准,避免仅依赖癌症登记PSA值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to characterize the effects of prostate specific antigen registry errors on clinical research by comparing cohorts based on cancer registry prostate specific antigen values with those based directly on results in the electronic health record. MATERIALS AND METHODS: We defined sample cohorts of men with prostate cancer using data from the Veterans Health Administration, including those with a prostate specific antigen value less than 4.0, 4.0 to 10.0, 10.0 to 20.0 and 20.0 to 98.0 ng/ml, respectively. We compared the composition of each cohort and overall patient survival when using prostate specific antigen values from the Veteran Affairs Central Cancer Registry vs the gold standard electronic health record laboratory file results. RESULTS: There was limited agreement among cohorts when defined by cancer registry prostate specific antigen values vs the laboratory file of the electronic health record. The least agreement of 58% was seen in patients with prostate specific antigen less than 4.0 ng/ml and greatest agreement of 89% was noted among patients with prostate specific antigen between 4.0 and 10.0 ng/ml. In each cohort patients assigned to a cohort based only on the cancer registry prostate specific antigen value had significantly different overall survival when compared with patients assigned based on registry and laboratory file prostate specific antigen values. CONCLUSIONS: Cohorts based exclusively on cancer registry prostate specific antigen values may have high rates of misclassification that can introduce concerning differences in key characteristics and result in measurable differences in clinical outcomes.
引用
- Guo DP, Thomas IC, Mittakanti HR, et al. The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. J Urol. 2018. PMID: 29630980. doi:10.1016/j.juro.2018.03.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。